Alzheimer's Disease Market In The 7MM Is USD 5,048 Million In 2025, Analyses Delveinsight

Some facts of the Alzheimer's Disease Market Report are:

• In 2023, the United States held the largest share, accounting for around 54% of the total Alzheimer's disease market in the 7MM, compared to other major markets including the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In May 2025, the FDA granted Breakthrough Device designation to Fujirebio Diagnostics' Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, an in vitro blood test designed to detect amyloid plaques in adults aged 55 and older showing signs of Alzheimer's disease.
• In April 2025, the ApoE4 Alzheimer's Alliance, a new patient advocacy group, was launched to represent individuals carrying the ApoE4 gene. The Alliance seeks to address the unique needs of this community by collaborating with U.S. policymakers and the FDA, aiming to accelerate the development of innovative treatments and supportive policies for those affected by Alzheimer's disease.
• According to DelveInsight, the total diagnosed prevalent cases of Alzheimer's disease in Japan were approximately 3,920 thousand in 2023.
• In 2023, the United States accounted for about 44% of diagnosed Alzheimer's disease cases across the 7MM, totaling around 6,980 thousand cases, with numbers expected to rise by 2034.
• Leading Alzheimer's Disease companies working in the market are Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., Stemedica Cell Technologies, Inc. and many others.
• In February 2025, Annovis Bio's phase 3 Alzheimer's trial protocol was accepted, aiming to accelerate development and support a New Drug Application for buntanetap.
• In February 2025, Johnson & Johnson's posdinemab, an anti-tau therapy for Alzheimer's, was granted fast track designation, addressing tau pathology to slow cognitive decline.
• In January 2025, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in the U.S. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
• In October 2024, Annovis Bio Inc. announced that it successfully completed an End-of-Phase 2 meeting with the FDA for its Alzheimer's drug, buntanetap. The FDA has approved the progression to Phase 3 pivotal trials, following data demonstrating symptomatic improvement in patients with early Alzheimer's. Annovis is now poised to file New Drug Applications (NDAs) for both short-term and long-term efficacy in treating early Alzheimer's disease.
• In September 2024, Eli Lilly's Alzheimer's treatment, Kisunla (donanemab), has been approved in Japan, following its U.S. approval in July. Kisunla becomes the second amyloid-targeting therapy approved in Japan, after Eisai and Biogen's Leqembi (lecanemab). It is indicated for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia, who have confirmed amyloid pathology.
• In 2023, the United States represented the largest market for Alzheimer's disease, accounting for approximately 54% of the total market size across the 7MM, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2023, Germany had the largest market size for Alzheimer's disease among the EU countries, with USD 267 million, while the UK had the smallest market size, approximately USD 104 million.
• In 2023, the market size for Alzheimer's disease in Japan was estimated to be approximately USD 845 million.
• According to DelveInsight's assessment, the total diagnosed prevalent cases of Alzheimer's disease in Japan were estimated to be approximately 3.92 million in 2023.
• In 2023, the United States accounted for about 44% of the diagnosed Alzheimer's disease cases across the 7MM, with approximately 6.98 million cases. This number is expected to grow by 2034, according to DelveInsight's estimates.
• In Japan, there were approximately 1.39 million diagnosed male cases and 2.53 million diagnosed female cases of Alzheimer's disease in 2023, reflecting the gender distribution within the population.
• In the US, age-specific cases of Alzheimer's disease are divided into four groups: under 65, 65–74, 75–84, and 85+ years. In 2023, the 75–84 age group had the highest prevalence, with approximately 2.79 million cases, while the under-65 group had the lowest, with around 175 thousand cases.
• Key Alzheimer's Disease Therapies: BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin, others.
• The Alzheimer's Disease epidemiology based on gender analyzed that more women than men have Alzheimer's or other dementias

Alzheimer's disease Overview

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and impaired daily functioning. It is the most common cause of dementia, primarily affecting older adults. The disease results from the accumulation of amyloid-beta plaques and tau tangles in the brain, leading to neuronal damage. Early symptoms include forgetfulness and difficulty planning, which gradually progress to severe cognitive and behavioral changes. With rising global aging populations, Alzheimer's prevalence is increasing significantly. Although current treatments offer symptomatic relief, emerging disease-modifying therapies targeting underlying pathology are driving advancements in care and shaping the future therapeutic landscape.